NO2516457T3 - - Google Patents

Info

Publication number
NO2516457T3
NO2516457T3 NO10791039A NO10791039A NO2516457T3 NO 2516457 T3 NO2516457 T3 NO 2516457T3 NO 10791039 A NO10791039 A NO 10791039A NO 10791039 A NO10791039 A NO 10791039A NO 2516457 T3 NO2516457 T3 NO 2516457T3
Authority
NO
Norway
Application number
NO10791039A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43601078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2516457(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2516457T3 publication Critical patent/NO2516457T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
NO10791039A 2009-12-21 2010-12-17 NO2516457T3 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28856209P 2009-12-21 2009-12-21
PCT/US2010/060925 WO2011084664A1 (en) 2009-12-21 2010-12-17 HUMANIZED FCγ R MICE

Publications (1)

Publication Number Publication Date
NO2516457T3 true NO2516457T3 (hu) 2018-08-11

Family

ID=43601078

Family Applications (1)

Application Number Title Priority Date Filing Date
NO10791039A NO2516457T3 (hu) 2009-12-21 2010-12-17

Country Status (25)

Country Link
US (8) US8658154B2 (hu)
EP (3) EP3498730A1 (hu)
JP (4) JP5595517B2 (hu)
KR (4) KR102092744B1 (hu)
CN (2) CN102762590B (hu)
AU (3) AU2010339863B2 (hu)
CA (2) CA2784953C (hu)
CY (1) CY1120316T1 (hu)
DK (1) DK2516457T3 (hu)
ES (1) ES2671188T3 (hu)
HK (1) HK1257001A1 (hu)
HR (1) HRP20180911T1 (hu)
HU (1) HUE038684T2 (hu)
IL (4) IL220365A (hu)
LT (1) LT2516457T (hu)
MY (1) MY156743A (hu)
NO (1) NO2516457T3 (hu)
PL (1) PL2516457T3 (hu)
PT (1) PT2516457T (hu)
RS (1) RS57280B1 (hu)
RU (1) RU2549695C2 (hu)
SG (3) SG10202011814TA (hu)
SI (1) SI2516457T1 (hu)
TR (1) TR201808011T4 (hu)
WO (1) WO2011084664A1 (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2784953C (en) * 2009-12-21 2018-05-22 Regeneron Pharmaceuticals, Inc. Humanized fc.gamma.r mice
MY172726A (en) * 2011-10-28 2019-12-11 Regeneron Pharma Humanized il-6 and il-6 receptor
RU2014120375A (ru) * 2011-11-01 2015-12-10 Рош Гликарт Аг Модель антителозависимой клеточной цитотоксичности в живом организме
WO2014071397A2 (en) * 2012-11-05 2014-05-08 Regeneron Pharmaceuticals Genetically modified non-human animals and methods of use thereof
DE202014010413U1 (de) 2013-09-18 2015-12-08 Kymab Limited Zellen und Organismen
PL2908626T3 (pl) * 2013-10-15 2017-05-31 Regeneron Pharmaceuticals, Inc. Zwierzęta z humanizowaną
RU2685914C1 (ru) 2013-12-11 2019-04-23 Регенерон Фармасьютикалс, Инк. Способы и композиции для направленной модификации генома
CA2942697A1 (en) * 2014-03-21 2015-09-24 Lynn Macdonald Non-human animals that make single domain binding proteins
PL3129400T3 (pl) 2014-04-08 2020-09-07 Regeneron Pharmaceuticals, Inc. Zwierzęta inne niż człowiek mające humanizowane receptory fc-gamma
KR102457921B1 (ko) * 2014-12-09 2022-10-25 리제너론 파마슈티칼스 인코포레이티드 인간화 분화 클러스터 274 유전자를 갖는 비인간 동물
PT3282835T (pt) * 2015-04-13 2023-07-25 Univ Yale Ratinhos knockin de sirpa-il15 humanizadas e métodos de utilização dos mesmos
WO2016175285A1 (ja) * 2015-04-30 2016-11-03 株式会社特殊免疫研究所 ヒト特定分子およびヒトＦｃγ受容体ファミリーを発現するトランスジェニック非ヒト動物
AU2019242586A1 (en) 2018-03-26 2020-10-01 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
EP3861854A4 (en) * 2018-09-27 2022-01-26 Central Institute For Experimental Animals IMMUNODEFICIENCY MOUSE
JP6935383B2 (ja) * 2018-09-27 2021-09-15 公益財団法人実験動物中央研究所 免疫不全マウス
WO2020172505A1 (en) 2019-02-22 2020-08-27 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
KR20230147048A (ko) 2020-12-16 2023-10-20 리제너론 파마슈티칼스 인코포레이티드 인간화 Fc 알파 수용체를 발현하는 마우스
JP7131650B1 (ja) 2021-04-28 2022-09-06 井関農機株式会社 脱穀装置

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0149012B1 (ko) 1988-05-27 1998-08-17 쇼트보르그 레기날드 데 사람 f크롬 수용체 iii
EP0814159B1 (en) * 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5258359A (en) * 1991-08-02 1993-11-02 Monsanto Company Glyphosant-containing herbicidal compositions comprising acetylenic diol rainfastness enhancing agents
EP0663952A4 (en) 1992-09-11 1997-06-11 Univ California TRANSGENIC NON-HUMAN ANIMALS WITH TARGETED INTERRUPTED TRANSDUCTION GENES IN LYMPHOCYTES.
US5877396A (en) * 1993-04-23 1999-03-02 Sloan Kettering Institute For Cancer Research Mice mutant for functional Fc receptors and method of treating autoimmune diseases
US6111166A (en) 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
EP0942968B1 (en) 1996-12-03 2008-02-27 Amgen Fremont Inc. Fully human antibodies that bind EGFR
US5899312A (en) * 1997-07-22 1999-05-04 Lucent Technologies Inc Anti-fraud string grabbing device
US6676927B1 (en) 1999-01-20 2004-01-13 The Rockefeller University Animal model and methods for its use in the selection of cytotoxic antibodies
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
JP2003531149A (ja) 2000-04-13 2003-10-21 ザ・ロツクフエラー・ユニバーシテイ 抗体由来の免疫応答の増強
RU2262511C2 (ru) * 2000-05-18 2005-10-20 Джапан Тобакко, Инк. Человеческое моноклональное антитело против ailim, костимулирующей молекулы передачи сигнала, и его фармацевтическое применение
AU2002222951A1 (en) 2000-07-18 2002-01-30 Geoff D. Koch Apparatus and method for maintaining control of a drilling machine
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
FR2822161B1 (fr) 2001-03-15 2003-09-19 Genoway Cellule et animal transgenique modelisant les reponses humaines allergiques mediees par les ige, et leurs utilisations
JP4653915B2 (ja) 2001-10-29 2011-03-16 独立行政法人科学技術振興機構 全身性エリテマトーデスモデル非ヒト動物
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2003104459A1 (en) 2002-06-07 2003-12-18 Arthron Limited Fcyriia transgenic animal model for autoimmune disease
JP2004147535A (ja) 2002-10-29 2004-05-27 Japan Science & Technology Agency ギラン・バレー症候群及び／又はフィッシャー症候群発症モデル非ヒト動物
KR20050084317A (ko) * 2002-12-16 2005-08-26 제넨테크, 인크. 인간 ｃｄ２０ 및(또는) ｃｄ１６을 발현하는 트랜스제닉마우스
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
KR101149242B1 (ko) * 2004-01-12 2012-05-25 어플라이드 몰리큘라 에볼류션, 인코포레이티드 Ｆｃ 영역 변이체
EP2767161B1 (en) 2004-10-19 2018-02-07 Regeneron Pharmaceuticals, Inc. Method for generating an non-human animal homozygous for a genetic modification
AU2006299429B2 (en) * 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
JP2009529331A (ja) 2006-03-10 2009-08-20 マクロジェニクス，インコーポレーテッド 変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法
US20080003225A1 (en) 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
MX2009002414A (es) * 2006-09-08 2009-05-20 Medimmune Llc Anticuerpos anti-cd19 humanizados y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunitaria.
HU0700534D0 (en) * 2006-11-24 2007-10-29 Mezoegazdasagi Biotechnologiai Transgenic animal with enhanced immune response and method for the preparation thereof
PL2178916T3 (pl) 2007-07-31 2015-08-31 Regeneron Pharma Ludzkie przeciwciała przeciwko ludzkiemu CD20 i sposób ich zastosowania
US20110119779A1 (en) * 2007-12-10 2011-05-19 Aliva Biopharmaceuticals, Inc. Methods for sequential replacement of targeted region by homologous recombination
ES2665068T3 (es) 2008-03-07 2018-04-24 Regeneron Pharmaceuticals, Inc. Ratones derivados de células ES a partir de inyección de un embrión hospedador diploide
EP2318439A2 (en) * 2008-07-23 2011-05-11 Rappaport Family Institute for Research in the Medical Sciences Methods of altering peripheral b cell populations and uses thereof
CA2784953C (en) * 2009-12-21 2018-05-22 Regeneron Pharmaceuticals, Inc. Humanized fc.gamma.r mice
US8883496B2 (en) * 2009-12-21 2014-11-11 Regeneron Phamaceuticals, Inc. Humanized FcgR mice

Also Published As

Publication number Publication date
US20140157445A1 (en) 2014-06-05
US8658154B2 (en) 2014-02-25
TR201808011T4 (tr) 2018-06-21
PL2516457T3 (pl) 2018-08-31
ES2671188T3 (es) 2018-06-05
IL242719A (en) 2017-09-28
SI2516457T1 (en) 2018-08-31
KR20190045404A (ko) 2019-05-02
HRP20180911T1 (hr) 2018-07-13
IL261257B (en) 2019-12-31
JP2013514778A (ja) 2013-05-02
KR102092744B1 (ko) 2020-03-24
SG181690A1 (en) 2012-07-30
SG10201408415PA (en) 2015-01-29
AU2014210646A1 (en) 2014-08-28
CY1120316T1 (el) 2019-07-10
JP2014132909A (ja) 2014-07-24
KR20200033981A (ko) 2020-03-30
US20200061213A1 (en) 2020-02-27
CN104232589B (zh) 2018-04-27
AU2010339863A1 (en) 2012-07-12
JP6073840B2 (ja) 2017-02-01
US9687566B2 (en) 2017-06-27
EP2516457A1 (en) 2012-10-31
CN104232589A (zh) 2014-12-24
US9056130B2 (en) 2015-06-16
IL220365A0 (en) 2012-08-30
AU2010339863B2 (en) 2014-07-17
IL271083A (en) 2020-01-30
EP2516457B9 (en) 2021-09-29
EP3336102A2 (en) 2018-06-20
EP3498730A1 (en) 2019-06-19
CA2784953A1 (en) 2011-07-14
PT2516457T (pt) 2018-06-12
SG10202011814TA (en) 2021-01-28
IL220365A (en) 2016-11-30
AU2014210645A1 (en) 2014-08-28
DK2516457T3 (en) 2018-06-18
MY156743A (en) 2016-03-31
AU2014210646B2 (en) 2016-06-23
RS57280B1 (sr) 2018-08-31
CA3000246C (en) 2021-05-25
HK1257001A1 (zh) 2019-10-11
KR20180058860A (ko) 2018-06-01
US20210346522A1 (en) 2021-11-11
CA3000246A1 (en) 2011-07-14
CA2784953C (en) 2018-05-22
US20110154512A1 (en) 2011-06-23
US20150313195A1 (en) 2015-11-05
US11020495B2 (en) 2021-06-01
RU2012131296A (ru) 2014-01-27
AU2014210645B2 (en) 2016-05-19
US9089599B2 (en) 2015-07-28
JP5595517B2 (ja) 2014-09-24
WO2011084664A1 (en) 2011-07-14
US10426848B2 (en) 2019-10-01
JP5891259B2 (ja) 2016-03-22
CN102762590A (zh) 2012-10-31
HUE038684T2 (hu) 2018-11-28
KR101862277B1 (ko) 2018-06-01
US8658853B2 (en) 2014-02-25
JP2016093201A (ja) 2016-05-26
US20180015185A1 (en) 2018-01-18
LT2516457T (lt) 2018-06-11
IL261257A (en) 2018-10-31
KR102178064B1 (ko) 2020-11-12
CN102762590B (zh) 2015-11-25
JP2014209923A (ja) 2014-11-13
EP2516457B1 (en) 2018-03-14
EP3336102A3 (en) 2018-08-01
US20120260357A1 (en) 2012-10-11
KR101973524B1 (ko) 2019-09-02
RU2549695C2 (ru) 2015-04-27
KR20120102138A (ko) 2012-09-17
US20140154701A1 (en) 2014-06-05

Similar Documents

Publication Publication Date Title
BR112012012396A2 (hu)
BR112012008267A2 (hu)
BR112012008195A2 (hu)
BRPI0925311A2 (hu)
BRPI0924307A2 (hu)
BR122021004633A2 (hu)
BR122017024704A2 (hu)
BR112012012487A2 (hu)
BR112012003853A2 (hu)
BR112012012080A2 (hu)
BR112012009797A2 (hu)
BR112012009446A2 (hu)
BR112012009703A2 (hu)
BR112012010357A2 (hu)
BR112012007656A2 (hu)
BR122019005883A2 (hu)
BR112012014856A2 (hu)
BRPI0924534A2 (hu)
BR112012007654A2 (hu)
BR112012007672A2 (hu)
BR112012005951A2 (hu)
BRPI0924617A2 (hu)
BR122017013721A2 (hu)
BR112012009404A2 (hu)
BR112012016234A2 (hu)